MX418110B - Dispersiones solidas y composiciones farmaceuticas que comprenden un indano sustituido y metodos para la preparacion y uso de las mismas - Google Patents
Dispersiones solidas y composiciones farmaceuticas que comprenden un indano sustituido y metodos para la preparacion y uso de las mismasInfo
- Publication number
- MX418110B MX418110B MX2021005038A MX2021005038A MX418110B MX 418110 B MX418110 B MX 418110B MX 2021005038 A MX2021005038 A MX 2021005038A MX 2021005038 A MX2021005038 A MX 2021005038A MX 418110 B MX418110 B MX 418110B
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- solid dispersions
- pharmaceutical compositions
- preparation
- substituted indane
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C317/22—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dispersion Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862752685P | 2018-10-30 | 2018-10-30 | |
| PCT/US2019/057725 WO2020092100A1 (en) | 2018-10-30 | 2019-10-23 | Solid dispersions and pharmaceutical compositions comprising a substituted indane and methods for the preparation and use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2021005038A MX2021005038A (es) | 2021-06-15 |
| MX418110B true MX418110B (es) | 2024-11-07 |
Family
ID=70464349
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021005038A MX418110B (es) | 2018-10-30 | 2019-10-23 | Dispersiones solidas y composiciones farmaceuticas que comprenden un indano sustituido y metodos para la preparacion y uso de las mismas |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US12358870B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3873443A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7425794B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102991240B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN112955130A (cg-RX-API-DMAC7.html) |
| MX (1) | MX418110B (cg-RX-API-DMAC7.html) |
| MY (1) | MY209101A (cg-RX-API-DMAC7.html) |
| SG (1) | SG11202104208RA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020092100A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3173831A1 (en) | 2020-03-19 | 2021-09-23 | Arcus Biosciences, Inc. | Tetralin and tetrahydroquinoline compounds as inhibitors of hif-2alpha |
| CN115697307A (zh) * | 2020-06-19 | 2023-02-03 | 葛兰素史密斯克莱知识产权(第2 号)有限公司 | 包含达普司他的制剂 |
| IL303390A (en) | 2020-12-03 | 2023-08-01 | Battelle Memorial Institute | Compositions of polymer nanoparticles and DNA nanostructures and methods for non-viral transport |
| WO2022216977A1 (en) | 2021-04-07 | 2022-10-13 | Batelle Memorial Institute | Rapid design, build, test, and learn technologies for identifying and using non-viral carriers |
| US11827614B2 (en) | 2021-05-21 | 2023-11-28 | Merck Sharp & Dohme Llc | Synthetic pathway to belzutifan and crystalline phases of synthetic intermediates |
| US20240327929A1 (en) * | 2021-08-12 | 2024-10-03 | Merck Sharp & Dohme Llc | Dosage regimen for administration of belzutifan |
| US12145901B1 (en) | 2021-09-17 | 2024-11-19 | Arcus Biosciences, Inc. | Process for preparing tetralin compounds |
| AU2023407370A1 (en) * | 2022-12-22 | 2025-07-03 | Cogent Biosciences, Inc. | Bezuclastinib formulations |
| WO2025072751A1 (en) | 2023-09-29 | 2025-04-03 | Battelle Memorial Institute | Polymer nanoparticle compositions for in vivo expression of polypeptides |
| KR102824931B1 (ko) * | 2023-10-17 | 2025-07-08 | 주식회사 참인티그레이션 | 오일 유화 공법을 이용하여 제조되는 반려동물 건강 영양제 및 이의 제조방법 |
| AU2024393766A1 (en) | 2023-12-08 | 2026-06-18 | Battelle Memorial Institute | Use of dna origami nanostructures for molecular information based data storage systems |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4932412A (en) | 1986-12-18 | 1990-06-12 | Immunomedics, Inc. | Intraoperative and endoscopic tumor detection and therapy |
| DE60038624T2 (de) | 1999-10-07 | 2009-06-10 | Aquilar-Cordova, Carlos, Estuardo, Newton | Methoden zur behandlung von festen tumoren und metastasen mit gentherapie |
| US7115265B1 (en) | 2001-05-14 | 2006-10-03 | Duke University | Four genetic tumor markers specific for human glioblastoma |
| CN101827585A (zh) | 2007-10-19 | 2010-09-08 | 雅培股份有限两合公司 | 含有n-芳基脲基化合物的固态分散体产品 |
| US8691866B2 (en) * | 2008-12-10 | 2014-04-08 | The General Hospital Corporation | HIF inhibitors and use thereof |
| TWI673051B (zh) | 2012-09-11 | 2019-10-01 | 美商梅維森前列腺療法有限責任公司 | 恩雜魯它脈(enzalutamide)之調和物 |
| CN105307636A (zh) | 2013-07-19 | 2016-02-03 | 西佳技术公司 | 非晶形特考韦瑞制备 |
| EP3417851B1 (en) | 2013-09-09 | 2020-07-22 | Peloton Therapeutics, Inc. | Aryl ethers and uses thereof |
| CN113209024A (zh) | 2013-12-31 | 2021-08-06 | 阿森迪亚制药有限责任公司 | 疏水性化合物的药物组合物 |
| US10512626B2 (en) | 2015-03-11 | 2019-12-24 | Peloton Therapeautics, Inc. | Compositions for use in treating glioblastoma |
-
2019
- 2019-10-23 CN CN201980071770.6A patent/CN112955130A/zh active Pending
- 2019-10-23 WO PCT/US2019/057725 patent/WO2020092100A1/en not_active Ceased
- 2019-10-23 MX MX2021005038A patent/MX418110B/es unknown
- 2019-10-23 EP EP19880015.3A patent/EP3873443A4/en active Pending
- 2019-10-23 US US17/286,581 patent/US12358870B2/en active Active
- 2019-10-23 MY MYPI2021002202A patent/MY209101A/en unknown
- 2019-10-23 KR KR1020217016289A patent/KR102991240B1/ko active Active
- 2019-10-23 SG SG11202104208RA patent/SG11202104208RA/en unknown
- 2019-10-23 JP JP2021523218A patent/JP7425794B2/ja active Active
-
2025
- 2025-06-30 US US19/254,916 patent/US20250326711A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3873443A1 (en) | 2021-09-08 |
| US12358870B2 (en) | 2025-07-15 |
| WO2020092100A1 (en) | 2020-05-07 |
| KR102991240B1 (ko) | 2026-07-21 |
| SG11202104208RA (en) | 2021-05-28 |
| CA3117563A1 (en) | 2020-05-07 |
| JP7425794B2 (ja) | 2024-01-31 |
| MX2021005038A (es) | 2021-06-15 |
| EP3873443A4 (en) | 2022-07-27 |
| MY209101A (en) | 2025-06-21 |
| US20210387946A1 (en) | 2021-12-16 |
| CN112955130A (zh) | 2021-06-11 |
| KR20210091191A (ko) | 2021-07-21 |
| US20250326711A1 (en) | 2025-10-23 |
| JP2022506062A (ja) | 2022-01-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021005038A (es) | Dispersiones solidas y composiciones farmaceuticas que comprenden un indano sustituido y metodos para la preparacion y uso de las mismas. | |
| CL2020003257A1 (es) | Compuestos antagonistas de pcsk9. | |
| CL2021000415A1 (es) | Vesículas derivadas de lactobacillus paracasei y uso de las mismas | |
| UY38403A (es) | Moduladores de la alfa-1 antitripsina | |
| ECSP20046463A (es) | Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas | |
| CL2017000902A1 (es) | Dihidropirrolopiridinas inhibidoras de ror-gamma | |
| UY38806A (es) | Compuestos inhibidores tricíclicos de kars dependientes de akr1c3, composiciones y sus usos | |
| MX2022002465A (es) | Inhibidores de kras g12d. | |
| CL2022001083A1 (es) | El uso de un modulador de empalme para un tratamiento que retrasa la progresión de la enfermedad de huntington | |
| BR112017013661A8 (pt) | Conjugado derivado de antraciclina (pnu), conjugado de fármaco-proteína de ligação (bpdc), método para a produção de um conjugado de fármaco-proteína de ligação (bpdc), uso de um conjugado de proteína de ligação-fármaco (bpdc) e composição farmacêutica | |
| MX2017015225A (es) | Inhibidores de la autotaxina y sus usos. | |
| MX386547B (es) | Combinación de un antagonista con muerte programada 1 (pd-1) y eribulina para el tratamiento de cáncer. | |
| MX386158B (es) | Derivados de 1,7-diaril-1,6-heptadien-3,5-diona, procedimiento para la preparación y uso de los mismos | |
| MX2017013875A (es) | Ciertos inhibidores de la proteína quinasa. | |
| MX2017006953A (es) | Medicamentos para disminuir la evolucion de la enfermedad de parkinson. | |
| CO2019008110A2 (es) | Activador de nrf2 | |
| MX2022002446A (es) | Compuestos de pirrolopirimidina inhibidores de perk. | |
| CL2020002101A1 (es) | Formulaciones de liberación sostenida de ácido bempedoico. | |
| MX2016014859A (es) | Composiciones farmaceuticas que comprenden danirixina para tratar enfermedades infecciosas. | |
| CL2018003338A1 (es) | Formulaciones inyectables fisiológicamente balanceadas de fosnetupitant. | |
| MX2019010060A (es) | Composiciones y metodo para tratar cancer. | |
| CO2017001712A2 (es) | Formulaciones de compuestos biológicos para instilación | |
| CL2021001922A1 (es) | Procedimientos para tratamiento de enfermedades con inhibidores de magl. | |
| CO2017002813A2 (es) | Derivados estabilizados de adrenomedulina y uso de los mismos | |
| CL2021000580A1 (es) | Uso de inhibidores de la caseina quinasa 1 para el tratamiento de enfermedades vasculares. |